Last reviewed · How we verify
NCT06606366: TARGET
Study on the Contribution of the Genetic Tumor Profile Obtained by Circulating Tumor DNA Analysis in the Multidisciplinary Molecular Biology Meeting of Eastern PACA
NA trial testing Blood sample taken for the liquid biopsy in Neoplasm Malignant in 238 participants. Currently enrolling.
3 June 2027
Quick facts
| Lead sponsor | Centre Antoine Lacassagne |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 238 |
| Start date | 3 March 2025 |
| Primary completion | 3 June 2027 |
| Estimated completion | 3 June 2027 |
| Sites | 1 location across France |
Drugs / interventions tested
- Blood sample taken for the liquid biopsy
Conditions studied
- Neoplasm Malignant — all drugs for Neoplasm Malignant →
Sponsor
Centre Antoine Lacassagne — full company profile →
Who can join
18 and older, any sex, with Neoplasm Malignant. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will evaluate the diagnostic performance of liquid biopsy for identifying molecular abnormalities among patients managed by the Multidisciplinary Molecular Biology Meeting. The gold standard considered in this study is the solid biopsy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06606366
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Neoplasm Malignant
Currently open trials in the same condition.
- NCT07209111 — A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014) · Phase 2 · recruiting
- NCT06782451 — Development of Preclinical Models Derived From Tumors With a Molecular Abnormality of Interest to Test Their Sensitivity · NA · recruiting
- NCT06575127 — Modified FOLFOXIRI Plus Target Therapy as a First Line Treatment for Advanced Colorectal Cancer a Prospective Phase Two · Phase 2 · recruiting
- NCT04987359 — A Trial of a Multimodal Lifestyle Intervention to Optimize Survivorship After Cancer · NA · active not recruiting
- NCT04976634 — Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016) · Phase 2 · active not recruiting
Other Centre Antoine Lacassagne trials
Trials by the same sponsor.
- NCT07429487 — Assessment of Adherence to Remotely Monitored Physical Activity Tracked on a Smartwatch, and Its Impact on Reducing Fati · NA · not yet recruiting
- NCT06782451 — Development of Preclinical Models Derived From Tumors With a Molecular Abnormality of Interest to Test Their Sensitivity · NA · recruiting
- NCT06400849 — Comparison of the Efficacy of Cryotherapy Combined With Compression in Preventing Neuropathy · NA · recruiting
- NCT06029218 — Analysis of the Toxicity and Efficacy of Daily 1 vs 2 Beam Proton Therapy · NA · recruiting
- NCT06058312 — Individual Food Preferences for the Mediterranean Diet in Cancer Patients · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06606366 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Antoine Lacassagne
- Last refreshed: 13 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06606366.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing